Antipsoriatic Effect of Fumaric Acid Derivatives. Results of a Multicenter Double-blind Study in 100 Patients

Overview

Journal J Am Acad Dermatol

Specialty Dermatology

Date 1994 Jun 1

PMID 8188891

Citations 75

Authors

P J Altmeyer

U Matthes

F Pawlak

K Hoffmann

P J Frosch

P Ruppert

S W Wassilew

T Horn

H W Kreysel

G Lutz

Affiliations

Soon will be listed here.

Abstract

Background: Psoriasis vulgaris may benefit from treatment with fumaric acid and/or its derivatives; however, because different preparations have been used, results have been contradictory and difficult to interpret.

Objective: The purpose of this clinical trial was to evaluate the therapeutic value of fumaric acid derivatives.

Methods: A randomized double-blind study was carried out in patients with psoriasis, comparing a well-characterized formulation of fumaric acid derivatives with placebo.

Results: The results indicated statistically significant superiority of the fumaric acid derivatives over placebo. Adverse events (flush, gastrointestinal disturbances) were initially relatively frequent, but decreased thereafter.

Conclusion: Fumaric acid derivatives were found to be effective and safe in the treatment of psoriasis.

Citing Articles

Novel potential pharmacological applications of dimethyl fumarate-an overview and update.

Bresciani G, Manai F, Davinelli S, Tucci P, Saso L, Amadio M Front Pharmacol. 2023; 14:1264842.

PMID: 37745068 PMC: 10512734. DOI: 10.3389/fphar.2023.1264842.

Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.

Sbidian E, Chaimani A, Guelimi R, Garcia-Doval I, Hua C, Hughes C Cochrane Database Syst Rev. 2023; 7:CD011535.

PMID: 37436070 PMC: 10337265. DOI: 10.1002/14651858.CD011535.pub6.

Monomethyl fumarate prevents alloimmune rejection in mouse heart transplantation by inducing tolerogenic dendritic cells.

Chen J, Cao Y, Jia O, Wang X, Luo Y, Cheuk Y Acta Biochim Biophys Sin (Shanghai). 2023; 55(5):866-877.

PMID: 37184280 PMC: 10281873. DOI: 10.3724/abbs.2023088.

Molecular and neuroimmune pharmacology of S1P receptor modulators and other disease-modifying therapies for multiple sclerosis.

Kihara Y, Chun J Pharmacol Ther. 2023; 246:108432.

PMID: 37149155 PMC: 10860660. DOI: 10.1016/j.pharmthera.2023.108432.

Shared Genetic Risk Factors for Multiple Sclerosis/Psoriasis Suggest Involvement of Interleukin-17 and Janus Kinase-Signal Transducers and Activators of Transcription Signaling.

Patrick M, Nair R, He K, Stuart P, Billi A, Zhou X Ann Neurol. 2023; 94(2):384-397.

PMID: 37127916 PMC: 10524664. DOI: 10.1002/ana.26672.